BeOne Medicines launches following redomiciliation

Sino-American biotech BeiGene has now effected its previously announced transition, becoming BeOne Medicines (Nasdaq: ONC; HKEX: 06160; SSE: 688235) and redomiciling to Switzerland, marking a significant milestone in the company’s evolution.

“BeOne represents more than a name change - it’s not only a reflection of who we are today as a leading global oncology company, but also our ambition to redefine what’s possible in oncology as we unite patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer,” said John Oyler, co-founder, chairman and chief executive at BeOne.

“While I know that our work is not done, I am extremely proud of the progress we have made with the explosive growth of Brukinsa as the backbone of our hematology franchise, the expansion of our PD-1 inhibitor, Tevimbra, and our potentially transformative oncology pipeline of more than 50 investigational assets, one of the most prolific in the industry. After 15 years of relentless innovation and strategic investment to boost our internal global capabilities, we are just getting started, and I look forward to working together as BeOne,” he added.